Hugues Fausther-Bovendo

Dr. Hugues Fausther-Bovendo


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
MNMarie-Edith Nepveu-Traversy
Marie-Edith Nepveu-Traversy
HFHugues Fausther-Bovendo
Hugues Fausther-Bovendo
GBGeorge Babuadze
George Babuadze
This comprehensive review explores the field of anti-tick vaccines, addressing their significance in combating tick-borne diseases of public health concern. The main objectives are to provide a brief epidemiology of diseases affecting humans and a thorough understanding of tick biology, traditional tick control methods, the development and mechanisms of anti-tick vaccines, their efficacy in field applications, associated challenges, and future prospects. Tick-borne diseases (TBDs) pose a significant and escalating threat to global health and the livestock industries due to the widespread distribution of ticks and the multitude of pathogens they transmit. Traditional tick control methods, such as acaricides and repellents, have limitations, including environmental concerns and the emergence of tick resistance. Anti-tick vaccines offer a promising alternative by targeting specific tick proteins crucial for feeding and pathogen transmission. Developing vaccines with antigens based on these essential proteins is likely to disrupt these processes. Indeed, anti-tick vaccines have shown efficacy in laboratory and field trials successfully implemented in livestock, reducing the prevalence of TBDs. However, some challenges still remain, including vaccine efficacy on different hosts, polymorphisms in ticks of the same species, and the economic considerations of adopting large-scale vaccine strategies. Emerging technologies and approaches hold promise for improving anti-tick vaccine development and expanding their impact on public health and agriculture.

26 August 2025 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
PDF file
MMMoufid Mhamadi
Moufid Mhamadi
GBGeorge (Giorgi) Babuadze
George (Giorgi) Babuadze
ABAminata Badji
Aminata Badji
MNMarie-Edith Nepveu-Traversy
Marie-Edith Nepveu-Traversy
ENEl Hadji Ndiaye
El Hadji Ndiaye
HFHugues Fausther-Bovendo
Hugues Fausther-Bovendo
Rift Valley Fever virus (RVFV) is a mosquito-borne zoonotic pathogen, that causes significant morbidity and mortality in livestock, including high abortion rates in pregnant animals and elevated case fatality in neonates, representing a major threat to both animal and human health. Vaccination is the most effective countermeasure to reduce RVFV’s impact. In this study, we designed a veterinary DNA vaccine encoding a consensus RVFV glycoprotein precursor (GPC), optimized for expression in sheep. The construct was evaluated for immunogenicity in mice and sheep and for protective efficacy in sheep raised under natural field conditions in Senegal, West Africa. The vaccine induced robust humoral responses characterized by high neutralizing antibody titers in both mice and sheep. Under natural exposure, vaccinated sheep showed reduced infection rates (3.2%) compared with controls (14.3%), and neutralizing antibody responses persisted for more than one year. Importantly, the vaccine was well tolerated, including in pregnant animals, with no adverse outcomes such as abortions or fetal abnormalities. These findings demonstrate that a DNA-based RVFV vaccine can elicit durable immunity and provide protection in livestock under real-world conditions. This study highlights the potential of DNA vaccines as a safe, effective, and affordable alternative to existing veterinary vaccines and supports their further development as a key strategy to reduce RVFV transmission and improve animal and human health outcomes in endemic regions.

29 March 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
ABAlice Berger
Alice Berger
JPJannie Pedersen
Jannie Pedersen
MKMonika M. Kowatsch
Monika M. Kowatsch
FSFlorine Scholte
Florine Scholte
MLMarc-Alexandre Christopher Lafrance
Marc-Alexandre Christopher Lafrance
GKGary Kobinger
Gary Kobinger
Currently, no effective vaccine to prevent human immunodeficiency virus (HIV) infection is available, and various platforms are being examined. The vesicular stomatitis virus (VSV) vaccine vehicle can induce robust humoral and cell-mediated immune responses, making it a suitable candidate for the development of an HIV vaccine. Here, we analyze the protective immunological impacts of recombinant VSV vaccine vectors that express chimeric HIV Envelope proteins (Env) in rhesus macaques. To improve the immunogenicity of these VSV-HIV Env vaccine candidates, we generated chimeric Envs containing the transmembrane and cytoplasmic tail of the simian immunodeficiency virus (SIV), which increases surface Env on the particle. Additionally, the Ebola virus glycoprotein was added to the VSV-HIV vaccine particles to divert tropism from CD4 T cells and enhance their replications both in vitro and in vivo. Animals were boosted with DNA constructs that encoded matching antigens. Vaccinated animals developed non-neutralizing antibody responses against both the HIV Env and the Ebola virus glycoprotein (EBOV GP) as well as systemic memory T-cell activation. However, these responses were not associated with observable protection against simian-HIV (SHIV) infection following repeated high-dose intra-rectal SHIV SF162p3 challenges.

5 March 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
HFHugues Fausther-Bovendo
Hugues Fausther-Bovendo
GBGeorge Babuadze
George Babuadze
TITeodora Ivanciuc
Teodora Ivanciuc
BKBirte Kalveram
Birte Kalveram
YQYue Qu
Yue Qu
GKGary Kobinger
Gary Kobinger
Background: Monoclonal antibodies (mAbs) are potent treatment options for infectious diseases. The rapid isolation and in vivo validation of therapeutic mAb candidates, including mAb cocktails, are essential to combat novel or rapidly mutating pathogens. The rapid selection and production of mAb candidates in sufficient amount and quality for preclinical studies are a major limiting step in the mAb development pipeline. Methods: Here, we developed a method to facilitate the screening of therapeutic mAbs in mouse models. Four conventional mAbs were transformed into single-chain variable fragments fused to the fragment crystallizable (Fc) region of a human IgG1 (scFv-IgG). These scFv-IgG were expressed individually or as a cocktail in vitro and in mice following transfection or hydrodynamic delivery of the corresponding plasmids. Results: This method induced high expression of all scFv-IgG and provided protection in two murine infection models. Conclusions: This study highlights the benefits of this approach for the rapid, low-cost screening of therapeutic mAb candidates.

1 September 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
BKBirte Kalveram
Birte Kalveram
AAAwadalkareem Adam
Awadalkareem Adam
JKJimmy Kapetshi
Jimmy Kapetshi
MWMeredith Weglarz
Meredith Weglarz
GBGeorge (Giorgi) Babuadze
George (Giorgi) Babuadze
HFHugues Fausther-Bovendo
Hugues Fausther-Bovendo
With sustained human-to-human transmission worldwide, Mpox virus remains a significant global health burden. However, there are no licensed therapeutics against Mpox, with clinical management limited to supportive care and pain management. Given the virus complex life cycles, effective treatments require the inhibition of both mature intracellular virions (MV) and extracellular virions (EV). Here, we describe the isolation of human monoclonal antibodies (mAbs) from antigen specific memory B cell using flow cytometry-based cell sorting. We also characterize the therapeutic potential of 2-mAb cocktails targeting both MV and EV using an in vitro neutralization assay and a mouse challenge model. Several developed human 2-mAb cocktails neutralized authentic Mpox in vitro . When administered 24 hours before or after Mpox challenge, the lead 2-mAb cocktail inhibited viral loads in mouse tissues, with the exception of the testes. Overall, our study identifies several human 2-mAb cocktails with therapeutic potential for controlling Mpox disease. SIGNIFICANCE: Mpox virus, which has emerged as a significant public health threat, is now endemic to several countries worldwide. Existing Mpox vaccines offer only partial protection, and the primary antiviral, tecovirimat, has demonstrated no clinical benefits, highlighting an urgent need for novel therapeutics. Recognizing the limitations of animal-derived antibodies for therapeutic use, we isolated human antibodies and demonstrated the therapeutic potential of two-antibody cocktails using an in vitro neutralization assay and a mouse challenge model. Importantly, the two antibodies within our lead cocktail were predicted to bind to conserved epitopes on their Mpox targets. Overall, this study documents the development of a human two-antibody cocktail with both prophylactic and therapeutic potential against Mpox, offering a promising new avenue for clinical intervention.